Switch theme
Sign up to access all valuation multiples
Beijing Scitop Bio-tech Co Ltd is engaged in production and sales of compound food additives, edible probiotic products and animal and plant micro-ecological preparations. The company engages in provision of biotechnology services, consulting, development, transfer; development and sale of stereotyped packaged food additives, compound food additives. Its products include Probio-M8 and Probio-M9.
2003
402
LTM Revenue $49.6M
LTM EBITDA $17.6M
$539M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scitop Bio-tech has a last 12-month revenue (LTM) of $49.6M and a last 12-month EBITDA of $17.6M.
In the most recent fiscal year, Scitop Bio-tech achieved revenue of $42.0M and an EBITDA of $18.8M.
Scitop Bio-tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scitop Bio-tech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $49.6M | XXX | $42.0M | XXX | XXX | XXX |
| Gross Profit | $28.4M | XXX | $24.5M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $17.6M | XXX | $18.8M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 45% | XXX | XXX | XXX |
| EBIT | $17.1M | XXX | $10.5M | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $14.8M | XXX | $13.1M | XXX | XXX | XXX |
| Net Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scitop Bio-tech's stock price is CNY 16 (or $2).
Scitop Bio-tech has current market cap of CNY 4.2B (or $586M), and EV of CNY 3.9B (or $539M).
See Scitop Bio-tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $539M | $586M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scitop Bio-tech has market cap of $586M and EV of $539M.
Scitop Bio-tech's trades at 12.8x EV/Revenue multiple, and 28.7x EV/EBITDA.
Equity research analysts estimate Scitop Bio-tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scitop Bio-tech has a P/E ratio of 39.5x.
See valuation multiples for Scitop Bio-tech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $586M | XXX | $586M | XXX | XXX | XXX |
| EV (current) | $539M | XXX | $539M | XXX | XXX | XXX |
| EV/Revenue | 10.9x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | 30.6x | XXX | 28.7x | XXX | XXX | XXX |
| EV/EBIT | 31.5x | XXX | 51.4x | XXX | XXX | XXX |
| EV/Gross Profit | 19.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 39.5x | XXX | 44.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -56.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScitop Bio-tech's last 12 month revenue growth is 33%
Scitop Bio-tech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $35K for the same period.
Scitop Bio-tech's rule of 40 is 74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scitop Bio-tech's rule of X is 118% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scitop Bio-tech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 74% | XXX | 78% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 118% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scitop Bio-tech acquired XXX companies to date.
Last acquisition by Scitop Bio-tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Scitop Bio-tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scitop Bio-tech founded? | Scitop Bio-tech was founded in 2003. |
| Where is Scitop Bio-tech headquartered? | Scitop Bio-tech is headquartered in China. |
| How many employees does Scitop Bio-tech have? | As of today, Scitop Bio-tech has 402 employees. |
| Is Scitop Bio-tech publicy listed? | Yes, Scitop Bio-tech is a public company listed on SHE. |
| What is the stock symbol of Scitop Bio-tech? | Scitop Bio-tech trades under 300858 ticker. |
| When did Scitop Bio-tech go public? | Scitop Bio-tech went public in 2020. |
| Who are competitors of Scitop Bio-tech? | Similar companies to Scitop Bio-tech include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Scitop Bio-tech? | Scitop Bio-tech's current market cap is $586M |
| What is the current revenue of Scitop Bio-tech? | Scitop Bio-tech's last 12 months revenue is $49.6M. |
| What is the current revenue growth of Scitop Bio-tech? | Scitop Bio-tech revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Scitop Bio-tech? | Current revenue multiple of Scitop Bio-tech is 10.9x. |
| Is Scitop Bio-tech profitable? | Yes, Scitop Bio-tech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Scitop Bio-tech? | Scitop Bio-tech's last 12 months EBITDA is $17.6M. |
| What is Scitop Bio-tech's EBITDA margin? | Scitop Bio-tech's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Scitop Bio-tech? | Current EBITDA multiple of Scitop Bio-tech is 30.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
